Dr. Uhm is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511Fax+1 507-284-0161
Education & Training
McGill University Faculty of MedicineClass of 1992, MD
Certifications & Licensure
MN State Medical License 1999 - 2025
TX State Medical License 1997 - 2004- Royal College of Physician of CanadaNeurology
Clinical Trials
- Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2001 Mar 01
- Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2006 May 01
- Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies Start of enrollment: 2006 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsShort-course hypofractionated proton beam therapy, incorporatingF-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnos...Sujay Vora, Deanna Pafundi, Molly Voss, Matthew Buras, Jonathan Ashman
The Lancet. Oncology. 2024-12-01 - Telehealth Utilization in Neuro-Oncology: Commentary on a Single Institution Experience After the COVID-19 Pandemic.Ugur Sener, Joon Uhm, Tufia Haddad, Joshua Pritchett
Current Oncology Reports. 2024-11-01 - Response to Letter by Zagardo, et al.Giovanna Grigsby-Rocca, Camilo Bermudez, Jessica D White, Bryan J Neth, Joon H Uhm
The Neurohospitalist. 2024-10-01
Press Mentions
Beating Back a Brain Tumor Amid LossJune 17th, 2019
Experts Present How Science and New Technology Are Driving New Brain Tumor Treatments and Improving Quality of LifeJuly 23rd, 2015
Brain Cancer Survival Improved Following FDA Approval of Bevacizumab, Mayo Study FindsFebruary 10th, 2016- Join now to see all
Grant Support
- Epidermal Growth Factor Receptor Signaling In GliomaNational Institute Of Neurological Disorders And Stroke2004–2006
- Soluble EGFR As A Potential Serum Biomarker In GliomaNational Cancer Institute2004
- Epidermal Growth Factor Receptor Signaling In GliomaNational Institute Of Neurological Disorders And Stroke2002–2003
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
